PMID- 19796283
OWN - NLM
STAT- MEDLINE
DCOM- 20100817
LR  - 20151113
IS  - 1468-1331 (Electronic)
IS  - 1351-5101 (Linking)
VI  - 17
IP  - 2
DP  - 2010 Feb
TI  - Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal 
      fluid of patients with amyotrophic lateral sclerosis.
PG  - 226-31
LID - 10.1111/j.1468-1331.2009.02775.x [doi]
AB  - BACKGROUND AND PURPOSE: Matrix metalloproteinases (MMPs) are implicated in the 
      pathogenesis of motor neuron degeneration in amyotrophic lateral sclerosis (ALS). 
      We investigated the expression of MMPs and tissue inhibitors of matrix 
      metalloproteinases (TIMPs) in serum and cerebrospinal fluid (CSF) correlating the 
      results with age, disease duration and the clinical course. METHODS: The material 
      consisted of 30 ALS patients and 15 age-matched healthy controls. ELISA method to 
      determine the expression of MT-MMP-1, MMP-2, MMP-9, TIMP-1 and TIMP-2 in serum 
      and CSF was used. MMP-2 and MMP-9 by zymography was also tested. RESULTS: In 
      serum MT-MMP-1, MMP-2, MMP-9 and TIMP-1 expression was increased, especially in 
      mild ALS cases. TIMP-2 values were normal. In CSF MT-MMP-1, MMP-2 and TIMP-1 
      level was either increased or normal, that of MMP-9 was decreased. TIMP-2 did not 
      change. No correlation of MMPs and TIMP-1 expression in serum and CSF and the age 
      of the patients was found. A correlation was observed between MMPs and TIMPs and 
      disease duration. CONCLUSIONS: Increased level of MMPs and TIMP-1 of ALS patients 
      may reflect the degeneration process of motor neurons and skeletal muscles and/or 
      is associated with tissues remodeling. The low level of MMP-9 in CSF may result 
      from impaired balance between MMP-9 and TIMP-1 and/or its increased intrathecal 
      degradation and physical clearance. Although the role of changed MMPs/TIMPs level 
      in the pathogenesis of ALS is not clear their analysis in serum may be used as 
      prognostic factor and a potential marker for monitoring treatment effects.
FAU - Niebroj-Dobosz, I
AU  - Niebroj-Dobosz I
AD  - Neuromuscular Unit, Medical Research Center, Polish Academy of Sciences, Warsaw, 
      Poland. dobosz@cmdik.pan.pl
FAU - Janik, P
AU  - Janik P
FAU - Sokolowska, B
AU  - Sokolowska B
FAU - Kwiecinski, H
AU  - Kwiecinski H
LA  - eng
PT  - Journal Article
DEP - 20091001
PL  - England
TA  - Eur J Neurol
JT  - European journal of neurology
JID - 9506311
RN  - 0 (Tissue Inhibitor of Metalloproteinase-1)
RN  - 0 (Tissue Inhibitor of Metalloproteinases)
RN  - 127497-59-0 (Tissue Inhibitor of Metalloproteinase-2)
RN  - EC 3.4.24.- (Matrix Metalloproteinases)
RN  - EC 3.4.24.24 (MMP2 protein, human)
RN  - EC 3.4.24.24 (Matrix Metalloproteinase 2)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
RN  - EC 3.4.24.7 (MMP1 protein, human)
RN  - EC 3.4.24.7 (Matrix Metalloproteinase 1)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Amyotrophic Lateral Sclerosis/*blood/*cerebrospinal fluid
MH  - Case-Control Studies
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Male
MH  - Matrix Metalloproteinase 1/blood/cerebrospinal fluid
MH  - Matrix Metalloproteinase 2/blood/cerebrospinal fluid
MH  - Matrix Metalloproteinase 9/blood/cerebrospinal fluid
MH  - Matrix Metalloproteinases/*blood/*cerebrospinal fluid
MH  - Middle Aged
MH  - Severity of Illness Index
MH  - Tissue Inhibitor of Metalloproteinase-1/blood/cerebrospinal fluid
MH  - Tissue Inhibitor of Metalloproteinase-2/blood/cerebrospinal fluid
MH  - Tissue Inhibitor of Metalloproteinases/*blood/*cerebrospinal fluid
EDAT- 2009/10/03 06:00
MHDA- 2010/08/18 06:00
CRDT- 2009/10/03 06:00
PHST- 2009/10/03 06:00 [entrez]
PHST- 2009/10/03 06:00 [pubmed]
PHST- 2010/08/18 06:00 [medline]
AID - ENE2775 [pii]
AID - 10.1111/j.1468-1331.2009.02775.x [doi]
PST - ppublish
SO  - Eur J Neurol. 2010 Feb;17(2):226-31. doi: 10.1111/j.1468-1331.2009.02775.x. Epub 
      2009 Oct 1.